Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan;
Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Japan.
Anticancer Res. 2023 Feb;43(2):707-711. doi: 10.21873/anticanres.16209.
BACKGROUND/AIM: A subset of patients with estrogen receptor (ER)-positive, HER2-negative, and node-negative breast cancer experience recurrences. Predicting patients who will have recurrences within 5 years of surgery is essential so that patients can be selected to receive adjuvant chemotherapy. The 95-gene classifier (95-GC) has been validated as a method to differentiate patients into high and low-risk groups for early recurrence.
In this study, we performed 95-GC analysis on 56 formalin-fixed paraffin-embedded (FFPE) tissue samples from patients who underwent surgery for ER-positive, HER2-negative, and node-negative breast cancer and did not receive adjuvant chemotherapy. We associated the obtained high- and low-risk groups with clinicopathological characteristics and recurrence-free survival (RFS).
We classified 12 out of 56 patients into the high-risk recurrence group. We found significantly higher KI67 scores in patients in the high-risk group. Other clinicopathological characteristics were not associated with the 95-GC risk groups. Patients in the 95-GC low-risk group had a significantly better prognosis than those in the high-risk group (p=0.0387). The 5-year RFS rate was 97.6% in the low-risk group and 74.1% in the high-risk group, while the 10-year RFS rates were 90.1% and 74.1%, respectively.
The 95-GC score can accurately predict RFS within 5 years of surgery for ER-positive, HER2-negative, and node-negative breast cancer using FFPE tissue samples. These prediction models could help assign patients to the most effective treatment regimen.
背景/目的：一部分雌激素受体（ER）阳性、HER2 阴性、淋巴结阴性的乳腺癌患者会出现复发。预测术后 5 年内复发的患者至关重要，以便选择患者接受辅助化疗。95 基因分类器（95-GC）已被验证为区分早期复发高风险和低风险患者的方法。
本研究对 56 例接受 ER 阳性、HER2 阴性、淋巴结阴性乳腺癌手术且未接受辅助化疗的患者的 56 例福尔马林固定石蜡包埋（FFPE）组织样本进行了 95-GC 分析。我们将获得的高风险和低风险组与临床病理特征和无复发生存（RFS）相关联。
我们将 56 例患者中的 12 例分类为高风险复发组。我们发现高风险组患者的 KI67 评分显著更高。其他临床病理特征与 95-GC 风险组无关。95-GC 低风险组患者的预后明显优于高风险组（p=0.0387）。低风险组的 5 年 RFS 率为 97.6%，高风险组为 74.1%，而 10 年 RFS 率分别为 90.1%和 74.1%。
使用 FFPE 组织样本，95-GC 评分可准确预测 ER 阳性、HER2 阴性、淋巴结阴性乳腺癌术后 5 年内的 RFS。这些预测模型可以帮助为患者分配最有效的治疗方案。
